Carbimazole
Carbimazole is a methimazole prodrug that is clinically used to treat hyperthyroidism and Graves’ disease; it exhibits immunomodulatory and anti-thyroid activities. Carbimazole inhibits thyroid peroxidase, decreasing production of thyroid hormones T3 and T4. In clinical subjects with Graves’ disease, carbimazole increases levels of IL-2 and free radical scavengers and decreases levels of IL-2Rs.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18848352
| Cas No. |
22232-54-8 |
|---|---|
| Purity |
≥98% |
| Formula |
C7H10N2O2S |
| Formula Wt. |
186.23 |
| Chemical Name |
2,3-Dihydro-3-methyl-2-thioxo-1H-imidazole-1- carboxylic acid ethyl ester |
| IUPAC Name |
ethyl 3-methyl-2-sulfanylideneimidazole-1-carboxylate |
| Synonym |
Athyromazole; Neo-mercazole; Neo-Thyreostat |
| Melting Point |
122-125°C |
| Solubility |
Soluble in water (500parts), ethanol (50parts), and chloroform (3parts). |
| Appearance |
White-almost white crystalline powder |
Manna D, Roy G, Mugesh G. Antithyroid drugs and their analogues: synthesis, structure, and mechanism of action. Acc Chem Res. 2013 Nov 19;46(11):2706-15. PMID: 23883148.
Wilson R, McKillop JH, Buchanan LM, et al. The effect of carbimazole therapy on interleukin 2, interleukin 2 receptors and free radicals. Autoimmunity. 1990;8(1):3-7. PMID: 2129783.
